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Essentials
 Type 3 von Willebrand’s disease is a rare bleeding disorders, with poorly characterized bleeding 
phenotype
 We conducted a multicenter, multinational observational study in patients previously diagnosed 
as type 3 VWD
 Analysis of 223 unrelated type 3 VWD patients disclosed a severe bleeding phenotype with 
intracranial bleeding, oral cavity, hemarthroses, and deep hematomas being at least five-fold 
more frequent in type 3 than in type 1 VWD and with clustering of bleeding symptoms within 
individual patients
 These findings represent the first systematic description of the clinical presentation of type 3 
VWD
Abstract
Background: Type 3 von Willebrand’s disease (VWD) patients present markedly reduced levels of von 
Willebrand factor and factor VIII. Because of its rarity, the bleeding phenotype of type 3 VWD is poorly 
described, as compared to type 1 VWD.
Aims: To evaluate the frequency and the severity of bleeding symptoms across age and sex groups in 
type 3 patients and to compare these with those observed in type 1 VWD patients; to investigate any 
possible clustering of bleeding symptoms within type 3 patients. 
Methods: We compared the bleeding phenotype and computed the bleeding score (BS) using the 
MCMDM-1VWD bleeding questionnaire in patients enrolled in the 3WINTERS-IPS and MCMDM-1VWD 
studies. 
Results: In 223 unrelated type 3 VWD patients, both the BS and the number of clinically relevant bleeding 
symptoms were increased in type 3 as compared to type 1 VWD patients (15. vs. 6.0 and 5 vs. 3). 
Intracranial bleeding, oral cavity, hemarthroses, and deep hematomas were at least five-fold over-
represented in type 3 VWD. A more severe bleeding phenotype was evident in patients having VWF:Ag 
levels <20 IU/dL at diagnosis in the two merged cohorts. In type 3 patients, there was an apparent 
clustering of hemarthrosis with gastrointestinal bleeding and epistaxis, whereas bleeding after surgery or 
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Conclusions: In the largest cohort of type 3 VWD patients, we were able to describe a distinct clinical 
phenotype that is associated with the presence of a more severe hemostatic defect.
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Introduction
Von Willebrand Disease (VWD) is an inherited disorder caused by a deficiency of the activity of 
von Willebrand factor (VWF), a multifunction plasma protein primarily binding to platelet GpIb and 
subendothelial collagen [1, 2]. The most prevalent form of VWD is type 1 VWD, having an autosomal 
dominant inheritance associated with a mild-to-moderate quantitative reduction of VWF. In contrast, 
autosomal recessive VWD, known as type 3 VWD (OMIN #277480), is characterized by a markedly severe 
deficiency of VWF, with nearly undetectable plasma levels of VWF antigen (VWF:Ag) and severely 
reduced factor VIII  [3-7]. Patients having type 3 VWD do not respond to treatment with desmopressin, 
and substitution treatment with plasma or recombinant VWF concentrates is usually required [8-10]. 
Type 3 VWD is caused by homozygous or compound heterozygous mutations in the gene encoding VWF, 
with some genotypes associating with an increased risk of alloantibody development after substitution 
treatment [11, 12]. 
Several multicenter, collaborative studies have described the bleeding phenotype of type 1 VWD, 
confirming the highly heterogeneous variability of bleeding severity [13-16]. The clinical phenotype in 
type 3 patients is less well-characterized because of the rarity of these patients, with an estimated 
prevalence of around 1 case per million that may increase in countries with consanguineous offspring 
[17]. The clinical manifestations most frequently reported are disproportionate mucocutaneous bleeding, 
severe menorrhagia, and hemophilia-like symptoms, such as muscle hematomas and joint bleeding [17-
19]. A more detailed description of the clinical phenotype of type 3 VWD patients would have relevant 
clinical implications, however, particularly taking into account the impact of bleeding symptoms in the 
patient’s quality of life and the associated socio-economic burden [20, 21].  
The type 3 Von Willebrand International RegistrieS Inhibitor Prospective Study (3WINTERS-IPS, 
registered at www.clinicaltrial.gov as NCT02460458) is a no-profit, investigator-initiated, multicenter, 
European-Iranian observational, retrospective and prospective study on patients with a diagnosis of type 
3 VWD. The study was designed to assess the clinical phenotype of type 3 VWD, describe its laboratory 
pattern and genetic background, and assess the safety and efficacy of therapeutic products for the 
prevention and treatment of bleeding symptoms.
In this study, we aimed at evaluating the clinical presentation of type 3 VWD patients enrolled by 
the 3WINTERS-IPS. We specifically aimed at describing the frequency of the different bleeding 
symptoms and comparing them with those reported by type 1 VWD patients. We hypothesized that type 
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but also qualitatively. We also wished to evaluate patterns of association between specific bleeding 
symptoms in type 3 patients.
Methods
Patient cohorts. The 3WINTERS-IPS enrolled patients from 22 Centers from 9 countries. We 
evaluated data originating from the first part of the study, having a cross-sectional design. Patients were 
eligible when having a documented bleeding history, VWF:Ag below 3 IU/dL, and an autosomal recessive 
inheritance based on phenotype analysis at the recruiting Centers [22, 23]. Clinical and laboratory data 
were obtained in an anonymized form from the MCMDM-1VWD study database, after having obtained 
consent from the MCMDM-1VWD study coordinator (I.P.).
Collection of the bleeding history. After signing an informed consent to participate in the study, all 
subjects were administered a bleeding questionnaire exploring the history of bleeding symptoms by a 
trained physician who queried patients in the local language.  For this retrospective phase, the MCMDM-
1VWD questionnaire was used to evaluate bleeding history, allowing an appropriate comparison between 
the two groups of patients [13]. Spontaneous bleeding symptoms (epistaxis, oral cavity bleeding, 
cutaneous bleeding, bleeding after minor wounds, hematomas, intracerebral bleeding, hemarthroses, 
menorrhagia) were collected from birth to the date of enrollment in the study. Bleedings after surgery, 
delivery, or tooth extraction were recorded only from the date of birth to the age of diagnosis since the 
appearance of these symptoms may have been influenced by medical treatment after diagnosis [13]. We 
calculated the Bleeding score (BS) according to the MCMDM-1VWD criteria and considering symptoms 
that occurred before the diagnosis of VWD. 
Laboratory measurements. In all investigated patients, we collected twenty ml of citrated blood 
samples with clean venipuncture at the time of recruitment. Platelet-poor plasma was immediately 
aliquoted and stored at –80 ˚C for subsequent measurements. In the 3WINTERS-IPS, VWF:Ag was 
centrally measured in Hamburg (Dr. U. Budde) using a sensitive VWF:Ag enzyme-linked assay, whereas 
in the MCMDM-1VWD study VWF:Ag was measured in Vicenza using a commercial assay (VWF Assay, 
Stago, France). Both measurements had an interassay coefficient of variation below 6% and were carried 
out against the WHO Standard for VWF/FVIII and expressed as IU/dL. For safety reasons, a wash-out 
period was not mandatory in eligible patients; we did, however, exclude from phenotype analyses those 
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Statistical methods. We used median and interquartile ranges to describe quantitative values, and 
median and chi-square statistic to test for statistical differences of quantitative and qualitative variables, 
respectively. We used the ratio between the frequency of each bleeding symptoms in type 3 and type 1 
VWD as a measure of association between a specific symptom and type 3 VWD; 95% CI were computed 
as for risk ratios [24]. When a symptom was not present (e.g., a central nervous system [CNS] bleeding in 
type 1 VWD), we imputed 0.5 instead of zero in that cell. If the lower 95% CI was higher than one, we 
assumed that the bleeding symptom was more frequently present in type 3 than in type 1 VWD. We 
compared only index cases, and affected family members enrolled in the MCMDM-1VWD study to type 3 
patients. In both cohorts, individual bleeding symptoms (e.g., epistaxis or menorrhagia) were considered 
as significant when having a score >1 (hence requiring medical attention). For instance, epistaxis was 
regarded as clinically relevant when severe enough for the patient to seek medical advice. For each 
subject enrolled in either the MCMDM-1 VWD study or the 3WINTERS-IPS, we used two measures as a 
proxy for the clinical severity of the bleeding phenotype: the MCMDM-1 VWD BS, and the total number 
of relevant bleeding symptoms presented by the patient. While the BS is a well-known index of bleeding 
severity, it is nonetheless influenced by the most severe symptom ever suffered by a patient. On the 
other hand, counting the number of different bleeding symptoms sustained by an individual patient may 
also be a relevant indicator of the overall bleeding tendency of that patient. In a previous study, we 
demonstrated that the number of bleeding symptoms has a diagnostic capability similar to that of the BS 
for the diagnosis of mild VWD [25]. We used two different regression models to study the relation 
between VWF:Ag and the bleeding phenotype in the two merged cohorts. Linear regression was used to 
model VWF:Ag dependent variations of the BS, while Poisson regression was used to study the changes 
in the number of clinically relevant symptoms. In both models, we included ABO blood type, age, and sex 
as covariates and, since the relation between VWF:Ag and bleeding risk is known to be nonlinear, we 
used four-knots cubic splines for VWF:Ag values [26, 27]. The relation between VWF:Ag and the bleeding 
risk was then evaluated by plotting the partial residuals against VWF:Ag in the two models (i.e., linear or 
Poisson regression); the frequency of bleeding at VWF:Ag equal to 100 IU/dL was considered as the 
baseline risk. We finally used the chi-square statistics and its associated standardized residuals to 
evaluate if the observed distribution of each possible symptom pairs (e.g., epistaxis and surgery, epistaxis 
and menorrhagia, epistaxis and cutaneous bleeding) deviated from the expected one in the 3Winters-IPS 
cohort. We then used a circos plot to graphically depict the relation between bleeding symptoms in type 
3 patients. In a circo plot, different symptoms are joined together by an arc whose bases are directly 
proportional to the number of individuals presenting the two signs together [28]. Hence, in a circo plot, 
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(symptom pairs). To reduce visual cluttering and to minimize the chances of model overfitting, we 
plotted only those relational pairs having a standardized residual corresponding to a p<0.001 in a chi-
square statistics, therefore indicating a statistical association even after Bonferroni adjustment for ten 
pair comparisons. The R statistical package was used for data analysis [29], using the circlize package for 
circos plots [30]. 
Results
Patient cohorts. The 3WINTERS-IPS enrolled a total of 265 unrelated patients, of whom we analyzed in 
the present study 223 patients with an available bleeding history at recruitment (Figure 1). The median 
age at study inclusion was 29 years, whereas the median age at diagnosis was two years (interquartile 
range, 1-6); 129 were females. There were 106 patients of Iranian descent, while the remaining patients 
were from Europe. Table 1 reports the clinical characteristics of patients enrolled in the 3Winters-IPS and 
the MCMDM-1VWD studies, respectively. The 3WINTERS-IPS and the MCMDM-1 VWD cohorts were 
similar as for sex distribution but differed significantly in terms of age of diagnosis and severity of clinical 
presentation. Both the median BS and the median number of clinically relevant bleeding symptoms were 
increased in type 3 patients.  There were 18 (8.1%) type 3 patients that had a normal BS at diagnosis, as 
compared with 138 (33.1%) type 1 patients. The ABO composition was also noticeably different, with an 
excess of blood O group patients in the type 1 MCMDM-1 VWD cohort. Since the ABO blood group was 
similarly distributed in Iranian and non-Iranian patients in the 3WINTERS-IPS cohort (p=0.48, chi-square 
test), this difference most likely reflects an influence of the ABO blood group in the diagnostic process of 
type 1 VWD. 
Bleeding symptoms in type 3 patients. Figure 2 panel A shows that epistaxis was the most frequent 
clinically relevant bleeding symptom in type 3 patients, followed by menorrhagia in females. Males had a 
higher frequency of hemarthroses and hematomas than females (53.4% vs. 42.1% and 40.8% vs. 27.1%, 
respectively). Panel B shows the ratio between the frequency of bleeding symptoms in type 3 and type 1 
patients, respectively. Surgical, post-extraction and post-partum bleeding, and menorrhagia were not 
specifically over-represented in type 3 VWD. In contrast, some bleeding symptoms (deep hematomas, 
hemarthroses, oral cavity, and CNS bleeding) were overrepresented (>five-fold) in type 3 VWD patients. 
When comparing the clinical presentation of type 3 vs. type 1 VWD, clearly increased bleeding scores 
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Relation between VWF:Ag at diagnosis and bleeding phenotype. We restricted this analysis in all patients 
enrolled in the MCMDM-1 VWD and in the 3WINTERS-IPS patients having VWF:Ag <3 IU/dL at the time 
of sampling (n=178). Thus, we excluded from this analysis 45 3WINTERS-IPS patients, mainly because 
they did receive some form of replacement therapy in the days before sampling (Figure 1). As shown in 
Figure 4, VWF:Ag levels at diagnosis below 30 IU/dL were associated with a steep increase of bleeding 
severity both in terms of increased BS (Panel A) and the number of bleeding symptoms (Panel B). To 
further investigate the relation between bleeding phenotype and VWF:Ag levels, we evaluated 
differences in patients with type 1 or 3 VWD at three different VWF:Ag cut-offs (<10, 10-30, and >30 
IU/dL) (Table 2). Patients with VWF:Ag below 30 IU/dL were younger, had a similar distribution of males 
and females, of O and non-O blood group, and were more symptomatic both in terms of BS and of the 
number of reported bleeding symptoms. 
Bleeding patterns in type 3 VWD patients. Based on clinical experience with VWD patients, we 
hypothesized that some symptoms might cluster together. If this hypothesis was correct, then the 
observed distribution of symptoms would not be that expected by their frequency at large in all patients.  
For instance, if epistaxis clusters with cutaneous bleeding, we would expect the observed frequency of 
cutaneous bleeding to be higher in patients with epistaxis than in those without. Figure 5, Panel A shows 
the association between all symptoms pairs, expressed in terms of standardized residuals of the chi-
square distribution (the darker the square, the higher the degree of the association, a standardized 
residual higher than five being statistically significant [31, 32]). Some symptoms pairs (cutaneous 
bleeding with epistaxis and post-surgical with post-extraction bleeding) were strongly associated 
together. Other significant associations were oral cavity bleeding with both post-surgical with post-
extraction bleeding and epistaxis with both hemarthrosis and GI bleeding. The circo plot in Figure 5, 
Panel B expands these findings, showing two distinct patterns of clustering. The first comprises the 
association of hemarthrosis with GI bleeding and epistaxis and, to a lesser extent, with deep hematomas. 
The second cluster of association of oral cavity bleeding with post-surgical or post-extraction bleeding 
and with menorrhagia.
Discussion
Type 3 VWD is an autosomal recessive or co-dominant disorder with a reported prevalence ranging from 
0.1 to 5.3 per million [33, 34].  Given its rarity, there are few systematic descriptions of the clinical 
phenotype of type 3 VWD patients, as is the case for type 1 VWD patients. The 3WINTERS-IPS is the first 
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phenotypic data, and therefore offers a unique opportunity for providing a full clinical picture of these 
rare disease patients. 
This study shows that the bleeding phenotype in type 3 VWD patients is remarkably different from that 
of type 1 patients, not only in terms of disease severity (BS or number of bleeding symptoms) but also in 
terms of clinical presentation. Type 3 VWD patients had an increased BS since the pediatric age, and their 
median age at diagnosis (2 years) may be considered consistent with that of the clinically most severe 
bleeding disorders. The median BS in our cohort was 15, a figure that is remarkably similar to that 
reported in the more limited WiN cohort [15]. Epistaxis is the most prevalent clinical symptom, followed 
by hemarthrosis in males and menorrhagia in females. However, by comparing the prevalence of 
bleeding symptoms in patients with type 3 and type 1 VWD, we were able to demonstrate that some 
bleeding manifestations were typically associated with type 3 patients (Figure 1, panel B). Central 
nervous system bleeding, although rare in type 3 patients, was not reported in the previous MCMDM-1 
VWD study, and we conservatively estimate that the prevalence of CNS bleeding is increased more than 
twenty-fold in type 3 than in type 1 patients.
Similarly, oral cavity bleeding, hemarthroses, and deep hematomas (especially muscle hematomas) were 
7 to 10-fold more prevalent in type 3 patients. All these symptoms had a rate ratio significantly higher 
than one, therefore suggesting that they may be considered distinctive for type 3 rather than type 1 
VWD. It is tempting to attribute this peculiar association not only to the more severely reduced VWF:Ag 
but also to the very low factor VIII levels, with a consequent clotting defect (rather than of primary 
hemostasis only) more resembling hemophilia. On the other hand, the prevalence of post-surgical or 
post-extraction bleeding was similar to that reported for type 1 VWD, possibly suggesting that the 
adoption of adequate treatments is sufficient to reduce bleeding severity despite the more severe factor 
defect.
Another significant study finding is the association between bleeding severity and factor levels measured 
at diagnosis. To adequately address this issue, we pooled clinical and retrospective laboratory data from 
the MCMDM-1 VWD type patients with those from type 3 patients, thus obtaining a spectrum of patients 
with a continuum of VWF:Ag ranging from 0.5 to 80 IU/dL and allowing the estimation of the relation 
between factor deficiency and clinical presentation. At this regard, a significant limitation of the present 
study is the lack of a specific metric unequivocally defining the bleeding severity, that is especially 
important when comparing bleeding disorders with different clinical phenotype, such as type 1 and type 
3 VWD. For these latter patients, the use of a tool such as the Bleeding Score may prove inaccurate, 
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recurrent severe bleeding symptoms (e.g., two or more hemarthroses). Thus, the BS emphasizes the 
importance of a bleeding disorder as a determinant of the “severity” (e.g., amount of blood loss) of a 
single symptom.
On the other hand, accounting for the total number of bleeding symptoms gives more importance to 
disease as a risk factor for “bleeding tendency” in all body tissues. Although none of these two metrics is 
a perfect substitute for the actual patient bleeding rate, we were able to demonstrate that the severity of 
VWD is significantly increased when the VWF:Ag levels drop below 30 IU/dL. Interestingly, patients with 
a VWF:Ag below 5 IU/dL had a still sizeable increase of BS, but a lower risk of an increased number of 
bleeding symptoms. We hypothesize that VWD patients with a more marked reduction of VWF (such as 
type 3 patients) may require the adoption of more intensive treatments (e.g., blood products or 
concentrates, surgery) to appropriately manage bleeding symptoms than patients with milder forms of 
VWD, with a consequent steeper increase of the association between the laboratory and clinical 
phenotype. 
Finally, we were able to show, for the first time, some non-random bleeding patterns in type 3 VWD. The 
first pattern includes the presence of hemarthroses with gastrointestinal bleeding, epistaxis in the same 
patient; other patients showed were the association of oral cavity bleeding, post-surgical, and post-
extraction bleeding. It is worth noting that we observed an association between the presence of mucous 
bleeding and post-surgical or post-extraction bleeding, also in type 1 VWD patients [13]. While the 
factors resulting in a particular bleeding pattern are unpredictable at the patient’s level, it is interesting to 
observe that some patients have a clinical picture resembling type 1 VWD, while others tend to present a 
more severe clinical presentation including hemarthroses and gastrointestinal bleeding, the latter 
symptom being possibly related to angiodysplasia [35]. 
Our study also has some weaknesses. First, as 41.5% of the enrolled patients were of Iranian origin, we 
cannot exclude that some genetic mutations may be recurrent in our study sample. Second, the 
MCMDM-1 VWD scoring system that was used in this retrospective study may be insensitive to describe 
severe bleeding disorders accurately [36]. 
These limitations notwithstanding, the present study represents the broadest available clinical 
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Table 1. Clinical and laboratory characteristics of investigated subjects. For quantitative variables, 







   Male 94 (42.2%) 175 (42.0%)
   Female 129 (57.8%) 242 (58.0%)
Age at study inclusion, years 29.0 (16.0, 43.0) 35.0 (20.0, 48.0) < 0.001
Number of symptoms at diagnosis 5.0 (4.0, 7.0) 3.0 (2.0, 5.0) < 0.001
Bleeding Score 15.0 (8.0, 20.0) 6.0 (3.0, 10.0) < 0.001
Bleeding Score class < 0.001
   ≤3 18 (8.1%) 138 (33.1%)
   4-7 33 (14.8%) 121 (29.0%)
   8-15 70 (31.4%) 129 (30.9%)
   >15 102 (45.7%) 29 (7.0%)
ABO blood group * < 0.001
   non-O 119 (54.6%) 160 (38.4%)
   O 99 (45.4%) 257 (61.6%)
Median VWF:Ag (IU/dL) at diagnosis 0.0 (0.0, 2.0) 35.0 (20.2, 52.0) < 0.001
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Table 2. Characteristics of investigated subjects of the combined cohorts of MCMDM-1VWD and 
3WINTERS-IPS stratified by VWF:Ag level. For quantitative variables, median and interquartile values are 
reported; p values were calculated with the median test. 











   Male 96 (43.4%) 56 (42.7%) 97 (40.4%)
   Female 125 (56.6%) 75 (57.3%) 143 (59.6%)
Median age at study 
inclusion, years
28.0 (16.0, 42.0) 34.0 (17.0, 48.0) 34.5 (20.8, 49.0) <0.001
Median number of 
symptoms at diagnosis
5.0 (4.0, 7.0) 3.0 (2.0, 5.0) 3.0 (2.0, 5.0) <0.001
Median Bleeding Score 13.0 (7.0, 18.0) 6.0 (3.0, 10.0) 5.0 (2.0, 10.0) <0.001
ABO blood group* 0.002
   non-O 113 (51.6%) 58 (44.3%) 85 (35.4%)
   O 106 (48.4%) 73 (55.7%) 155 (64.6%)
Study <0.001
   3WINTERS-IPS 178 (80.5%) 0 (0.0%) 0 (0.0%)
   MCMDM-1VWD 43 (19.5%) 131 (100.0%) 240 (100.0%)
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Legends to Figures
Figure 1. CONSORT flow-chart of patients enrolled in the 3WINTERS-IPS
Figure 2. Panel A: frequency of clinically relevant bleeding symptoms in male and female patients with 
type 3 VWD; numbers above bars represent percent frequency. Panel B: frequency ratios of symptoms in 
type 3 vs. type 1 VWD. The horizontal dashed line represents the equivalence (similar frequency, rate 
ratio=1); 95% confidence intervals around the ratio are depicted. When the lower 95% CI is above the 
equivalence line, the symptom is more frequently present in type 3 than in type 1 VWD. 
Figure 3. Distribution of bleeding score (BS) in the patients from the 3WINTERS-IPS (light gray boxes) 
and MCMDM-1 VWD cohorts (dark gray boxes) by age, showing that BS is higher in type 3 patients in all 
age categories. For both type 1 and type 3 patients, the BS reaches its highest values above age 50 and 
subsequently remains stable. 
Figure 4. Relationship between bleeding severity and VWF:Ag in the two merged cohorts, showing that 
bleeding severity increases for VWF:Ag levels below 30 IU/dL. VWF:Ag was modeled using a four-knots 
cubic spline, with a linear model used for Panel A and a Poisson model for Panel B. Black lines: primary 
model; gray lines: 95% CI. Panel A: relation between bleeding score (BS) and VWF:Ag; Panel B: relation 
between risk of having one or more clinically relevant bleeding symptoms and VWF:Ag. In both panels, 
the ordinate (y-axis) expresses the absolute increase of BS or relative risk related to VWF:Ag in regression 
model also adjusted for age, sex, and ABO blood type.
Figure 5. Association between all symptoms pairs in investigated patients of the 3WINTERS-IPS cohort. 
Panel A shows the chi-square standardized residuals: the darker the square, the higher the degree of 
association between two symptoms. Panel B: Circo plot depicting the relation between bleeding 
symptoms in type 3 VWD patients. Only bleeding symptoms having a score >1 were considered; the 
width of the strips is directly proportional to the number of patients having both symptoms (symptom 
pairs). To reduce visual cluttering, we report only those relational pairs having chi-square p<0.001. For 
each symptom, the numeric scale indicates the total number of observed combination pairs, and the 
width of the connecting string represents the number of observed combinations. For instance, in the 223 
investigated patients, cutaneous bleeding was present in 315 combinations of symptoms; in 54 patients, 
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